Meta-Analysis
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Jun 26, 2016; 4(3): 69-76
Published online Jun 26, 2016. doi: 10.13105/wjma.v4.i3.69
Efficacy, safety, and dose comparison of degarelix for the treatment of prostate cancer: A systematic review and meta-analysis
Cheng Fang, Cai-Liang Wu, Sha-Sha Liu, Long Ge, Jin-Liang Bai
Cheng Fang, Jin-liang Bai, Department of Urological, First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, China
Cai-Liang Wu, Department of Obstetrics and Gynecology, First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, China
Sha-Sha Liu, Department of Pathology, First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, China
Long Ge, Evidence-Based Medicine Center, Lanzhou University, Lanzhou 730000, Gansu Province, China
Author contributions: Fang C and Wu CL are co-first authors; Fang C and Wu CL wrote the manuscript; Fang C and Bai JL planed and designed the research; Wu CL and Ge L tested the feasibility of the study; Ge L performed the statistical analysis; all authors approved the final version of the manuscript.
Conflict-of-interest statement: None.
Data sharing statement: We declare that we have no additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jin-Liang Bai, Professor, Department of Urological, First Clinical Medical College of Lanzhou University, No. 1, Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. 541301922@qq.com
Telephone: +86-931-8356807
Received: January 3, 2016
Peer-review started: January 3, 2016
First decision: February 29, 2016
Revised: March 23, 2016
Accepted: April 21, 2016
Article in press: April 22, 2016
Published online: June 26, 2016
Processing time: 165 Days and 3 Hours
Core Tip

Core tip: This meta-analysis and systematic review aimed to compare the efficacy, safety, and dosage regimens of degarelix for prostate cancer. A total of seven papers from 6 randomized controlled trials were identified, involving 1204 patients. Degarelix was an useful option in the treatment of advanced prostate cancer, and degarelix 240/160 mg regimen was superior to 240/80 mg regimen.